Results 11 to 20 of about 4,025 (198)
BMC Veterinary Research, 2023 Background Previous studies have demonstrated that fidaxomicin, a macrocyclic lactone antibiotic used to treat recurrent Clostridioides difficile-associated diarrhea, also displays potent in vitro bactericidal activity against Clostridium perfringens ...
Sergio Álvarez-Pérez +4 more
doaj +3 more sources
A prospective, observational study of fidaxomicin use for infection in France
Journal of International Medical Research, 2021 Objective To describe the characteristics, management and outcomes of hospitalised patients with Clostridioides difficile infection (CDI) treated with and without fidaxomicin.
Benoit Guery +28 more
doaj +2 more sources
Fidaxomicin: A new fight against clostridium difficile-associated diarrhea
Muller Journal of Medical Sciences and Research, 2014 Clostridium difficile-associated diarrhea (CDAD) occurs commonly as a side effect of broad-spectrum antibiotics. Drugs approved for CDAD are only two of them, metronidazole and vancomycin.
Dick B. S. Brashier +2 more
doaj +2 more sources
Recent Advances in Mode of Action and Biosynthesis Studies of the Clinically Used Antibiotic Fidaxomicin [PDF]
CHIMIA, 2020 The natural product antibiotic fidaxomicin is a marketed drug for the treatment of bacterial infections in the gut. Due to its promising in vitro activities against Mycobacterium tuberculosis, the development of next generation fidaxomicin analogs is of ...
Andrea Dorst, Erik Jung, Karl Gademann
doaj +2 more sources
Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
Canadian Journal of Infectious Diseases and Medical Microbiology, 2016 Background. This analysis examined the efficacy of fidaxomicin versus vancomycin in 406 Canadian patients with Clostridium difficile infection (CDI), based on data from 2 randomized, clinical trials. Methods. Patients received fidaxomicin or vancomycin 1.
Christine Lee +6 more
doaj +2 more sources
Recurrent Clostridium difficile colitis in elderly: the role of fidaxomicin [PDF]
Clinical Management Issues, 2014 Clostridium difficile colitis is a substantial cause of in-hospital morbidity. Since the mortality attributable may be as high as 10%, a prompt and effective treatment is advisable.
Francesco Artom, Valerio Del Bono
doaj +2 more sources
Synthetic and Systems BiotechnologyThe anti-Clostridium difficile infection (CDI) drug fidaxomicin is a natural polyketide metabolite mainly produced by Micromonosporaceae, such as Actinoplanes deccanensis, Dactylosporangium aurantiacum, and Micromonospora echinospora.
Huang Xie +6 more
doaj +2 more sources
Total Synthesis of the Glycosylated Macrolide Antibiotic Fidaxomicin [PDF]
Organic Letters, 2015 The first enantioselective total synthesis of fidaxomicin, also known as tiacumicin B or lipiarmycin A3, is reported. This novel glycosylated macrolide antibiotic is used in the clinic for the treatment of Clostridium difficile infections. Key features of the synthesis involve a rapid and high-yielding access to the noviose, rhamnose, and orsellinic ...
Kaufmann Elias +3 more
openaire +5 more sources
Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
Infection and Drug Resistance, 2013 Fredy Chaparro-Rojas, Kathleen M MullaneDepartment of Medicine, Section of Infectious Diseases, University of Chicago, Chicago, IL, USAAbstract: The epidemiology of Clostridium difficile infections (CDI) has evolved during the last decades, with an ...
Chaparro-Rojas F, Mullane KM
doaj +1 more source
Antibiotics, 2022 (1) Background: Fidaxomicin has been shown to significantly reduce Clostridioides difficile infection (CDI) recurrences rates in randomized, controlled trials.
Ronald G. Hall +3 more
doaj +1 more source